Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > IMNP is about to release some data

<< Previous

Bullboard Posts

Next >>

Comment by HouseSpeaker007on Jul 18, 2018 9:05am

108 Views

Post# 28331748

RE:IMNP is about to release some data

Hampooo wrote: Get ready for a blastoff

[/quote

Data for a reverse stock split. Don't mislead people because you either bought way up high or below the bid. IMNP's market cap is $6 million U.S, how will they pay ICO royalties with a lower market cap in comparison. Doesn't make sense if you ask me.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record